STOCK TITAN

[Form 4] Cumberland Pharmaceuticals Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cumberland Pharmaceuticals Inc. (CPIX) – Form 4 filing, 11 Jul 2025

Chairman, CEO and 10% owner A. J. Kazimi reported a series of open-market purchases carried out automatically under a Rule 10b5-1 trading plan adopted on 14 Nov 2024. Between 02 Jun 2025 and 30 Jun 2025 he bought about 160 common shares in 20 small daily lots (mostly 8 shares, last lot 16 shares). Purchase prices ranged from $6.00 at the start of the period to $2.60 at month-end, implying an average cost close to $5.0 per share (≈ $800 total).

Kazimi’s direct beneficial ownership increased from 5,699,268 to 5,699,428 shares. No derivative securities were involved. Because the transactions represent <0.003% of his existing stake and were pre-scheduled, the filing is largely administrative, although consistent insider buying—despite the share-price decline—can be viewed as a minor vote of confidence.

Cumberland Pharmaceuticals Inc. (CPIX) – Comunicazione Form 4, 11 lug 2025

Il presidente, CEO e azionista con il 10% A. J. Kazimi ha segnalato una serie di acquisti sul mercato aperto effettuati automaticamente secondo un piano di trading Rule 10b5-1 adottato il 14 nov 2024. Tra il 2 giu 2025 e il 30 giu 2025 ha acquistato circa 160 azioni ordinarie in 20 piccoli lotti giornalieri (per lo più 8 azioni, l’ultimo lotto 16 azioni). I prezzi di acquisto sono variati da 6,00 $ all’inizio del periodo a 2,60 $ a fine mese, con un costo medio vicino a 5,0 $ per azione (circa 800 $ in totale).

La proprietà diretta di Kazimi è aumentata da 5.699.268 a 5.699.428 azioni. Non sono stati coinvolti strumenti derivati. Poiché le transazioni rappresentano meno del 0,003% della sua partecipazione esistente e sono state programmate in anticipo, la comunicazione ha un carattere principalmente amministrativo, anche se l’acquisto costante da parte di un insider — nonostante il calo del prezzo delle azioni — può essere interpretato come un piccolo segnale di fiducia.

Cumberland Pharmaceuticals Inc. (CPIX) – Presentación Formulario 4, 11 de julio de 2025

El presidente, CEO y propietario del 10% A. J. Kazimi reportó una serie de compras en el mercado abierto realizadas automáticamente bajo un plan de negociación Rule 10b5-1 adoptado el 14 de noviembre de 2024. Entre el 2 de junio de 2025 y el 30 de junio de 2025 compró aproximadamente 160 acciones ordinarias en 20 pequeños lotes diarios (principalmente 8 acciones, el último lote 16 acciones). Los precios de compra oscilaron entre al inicio del período y $2.60 al final del mes, lo que implica un costo promedio cercano a $5.0 por acción (≈ $800 en total).

La propiedad directa de Kazimi aumentó de 5,699,268 a 5,699,428 acciones. No se involucraron valores derivados. Dado que las transacciones representan menos del 0.003% de su participación existente y fueron programadas con anticipación, la presentación es en gran medida administrativa, aunque la compra constante por parte de un insider — a pesar de la caída del precio de las acciones — puede verse como un pequeño voto de confianza.

Cumberland Pharmaceuticals Inc. (CPIX) – Form 4 제출, 2025년 7월 11일

회장 겸 CEO이자 10% 지분 보유자 A. J. Kazimi는 2024년 11월 14일 채택된 Rule 10b5-1 거래 계획에 따라 자동으로 실행된 일련의 공개 시장 매수를 보고했습니다. 2025년 6월 2일부터 6월 30일까지 그는 20회에 걸쳐 소규모 일일 매수(대부분 8주씩, 마지막은 16주)를 통해 약 160주의 보통주를 매입했습니다. 매수가격은 기간 초반 $6.00에서 월말에는 $2.60로 변동했으며, 평균 매입 단가는 약 $5.0 주당 (총 약 $800)으로 추정됩니다.

Kazimi의 직접 지분은 5,699,268주에서 5,699,428주로 증가했습니다. 파생상품은 포함되지 않았습니다. 거래가 그의 기존 지분의 0.003% 미만이고 사전 계획된 것이므로, 제출은 주로 행정적 성격을 띠지만 주가 하락에도 불구하고 내부자의 지속적인 매수는 소규모 신뢰의 표시로 해석될 수 있습니다.

Cumberland Pharmaceuticals Inc. (CPIX) – Dépôt Formulaire 4, 11 juillet 2025

Le président, PDG et détenteur de 10% des parts A. J. Kazimi a déclaré une série d’achats sur le marché libre effectués automatiquement dans le cadre d’un plan de trading Rule 10b5-1 adopté le 14 novembre 2024. Entre le 2 juin 2025 et le 30 juin 2025, il a acheté environ 160 actions ordinaires en 20 petites transactions quotidiennes (principalement 8 actions, la dernière transaction 16 actions). Les prix d’achat variaient de 6,00 $ au début de la période à 2,60 $ en fin de mois, impliquant un coût moyen proche de 5,0 $ par action (≈ 800 $ au total).

La propriété directe de Kazimi est passée de 5 699 268 à 5 699 428 actions. Aucun instrument dérivé n’a été impliqué. Étant donné que les transactions représentent moins de 0,003% de sa participation existante et ont été planifiées à l’avance, le dépôt est principalement administratif, bien que l’achat régulier par un initié — malgré la baisse du cours de l’action — puisse être perçu comme un léger signe de confiance.

Cumberland Pharmaceuticals Inc. (CPIX) – Form 4 Einreichung, 11. Juli 2025

Der Vorsitzende, CEO und 10%-Eigentümer A. J. Kazimi meldete eine Reihe von automatischen Käufen am offenen Markt im Rahmen eines Rule 10b5-1 Handelsplans, der am 14. November 2024 eingeführt wurde. Zwischen dem 2. Juni 2025 und dem 30. Juni 2025 kaufte er etwa 160 Stammaktien in 20 kleinen täglichen Tranchen (meist 8 Aktien, die letzte Tranche 16 Aktien). Die Kaufpreise lagen zwischen 6,00 $ zu Beginn und 2,60 $ zum Monatsende, was auf durchschnittliche Kosten von etwa 5,0 $ pro Aktie (ca. 800 $ insgesamt) hindeutet.

Kazimis direkte Beteiligung stieg von 5.699.268 auf 5.699.428 Aktien. Es waren keine Derivate beteiligt. Da die Transaktionen weniger als 0,003% seines bestehenden Anteils ausmachen und vorab geplant waren, ist die Meldung überwiegend administrativer Natur, obwohl der kontinuierliche Insiderkauf – trotz fallender Aktienkurse – als kleines Vertrauenssignal gewertet werden kann.

Positive
  • Continued insider accumulation suggests management confidence, even as the share price declined over the period.
  • Use of a Rule 10b5-1 plan demonstrates proactive compliance with updated insider-trading regulations.
Negative
  • Purchase size is immaterial (<0.003% of holdings), offering little signaling value to institutional investors.
  • Sharp price drop during buying window (from $6.00 to $2.60) underscores recent share-price weakness.

Insights

TL;DR – Very small, pre-planned insider buy; negligible direct impact on valuation.

The CEO purchased ~160 shares over June under a 10b5-1 plan at prices that fell sharply mid-month. Dollar value (≈$0.8 k) is immaterial against his 5.7 m-share position and CPIX’s market cap, so no earnings or liquidity signal is implied. Still, continued buying as the stock slid toward $2.60 might modestly reassure retail holders that management sees longer-term value. Overall, I classify the disclosure as neutral with no forecast changes.

TL;DR – Procedural Form 4; signals alignment but lacks materiality.

The filing satisfies Section 16 requirements and highlights adherence to the newer Rule 10b5-1(c) affirmative defense. Because trades were automated, they do not indicate opportunistic timing. The minute volumes (0.003% ownership change) mean governance or control dynamics remain unchanged. Impact on shareholder rights, voting power, or takeover defenses is non-impactful.

Cumberland Pharmaceuticals Inc. (CPIX) – Comunicazione Form 4, 11 lug 2025

Il presidente, CEO e azionista con il 10% A. J. Kazimi ha segnalato una serie di acquisti sul mercato aperto effettuati automaticamente secondo un piano di trading Rule 10b5-1 adottato il 14 nov 2024. Tra il 2 giu 2025 e il 30 giu 2025 ha acquistato circa 160 azioni ordinarie in 20 piccoli lotti giornalieri (per lo più 8 azioni, l’ultimo lotto 16 azioni). I prezzi di acquisto sono variati da 6,00 $ all’inizio del periodo a 2,60 $ a fine mese, con un costo medio vicino a 5,0 $ per azione (circa 800 $ in totale).

La proprietà diretta di Kazimi è aumentata da 5.699.268 a 5.699.428 azioni. Non sono stati coinvolti strumenti derivati. Poiché le transazioni rappresentano meno del 0,003% della sua partecipazione esistente e sono state programmate in anticipo, la comunicazione ha un carattere principalmente amministrativo, anche se l’acquisto costante da parte di un insider — nonostante il calo del prezzo delle azioni — può essere interpretato come un piccolo segnale di fiducia.

Cumberland Pharmaceuticals Inc. (CPIX) – Presentación Formulario 4, 11 de julio de 2025

El presidente, CEO y propietario del 10% A. J. Kazimi reportó una serie de compras en el mercado abierto realizadas automáticamente bajo un plan de negociación Rule 10b5-1 adoptado el 14 de noviembre de 2024. Entre el 2 de junio de 2025 y el 30 de junio de 2025 compró aproximadamente 160 acciones ordinarias en 20 pequeños lotes diarios (principalmente 8 acciones, el último lote 16 acciones). Los precios de compra oscilaron entre al inicio del período y $2.60 al final del mes, lo que implica un costo promedio cercano a $5.0 por acción (≈ $800 en total).

La propiedad directa de Kazimi aumentó de 5,699,268 a 5,699,428 acciones. No se involucraron valores derivados. Dado que las transacciones representan menos del 0.003% de su participación existente y fueron programadas con anticipación, la presentación es en gran medida administrativa, aunque la compra constante por parte de un insider — a pesar de la caída del precio de las acciones — puede verse como un pequeño voto de confianza.

Cumberland Pharmaceuticals Inc. (CPIX) – Form 4 제출, 2025년 7월 11일

회장 겸 CEO이자 10% 지분 보유자 A. J. Kazimi는 2024년 11월 14일 채택된 Rule 10b5-1 거래 계획에 따라 자동으로 실행된 일련의 공개 시장 매수를 보고했습니다. 2025년 6월 2일부터 6월 30일까지 그는 20회에 걸쳐 소규모 일일 매수(대부분 8주씩, 마지막은 16주)를 통해 약 160주의 보통주를 매입했습니다. 매수가격은 기간 초반 $6.00에서 월말에는 $2.60로 변동했으며, 평균 매입 단가는 약 $5.0 주당 (총 약 $800)으로 추정됩니다.

Kazimi의 직접 지분은 5,699,268주에서 5,699,428주로 증가했습니다. 파생상품은 포함되지 않았습니다. 거래가 그의 기존 지분의 0.003% 미만이고 사전 계획된 것이므로, 제출은 주로 행정적 성격을 띠지만 주가 하락에도 불구하고 내부자의 지속적인 매수는 소규모 신뢰의 표시로 해석될 수 있습니다.

Cumberland Pharmaceuticals Inc. (CPIX) – Dépôt Formulaire 4, 11 juillet 2025

Le président, PDG et détenteur de 10% des parts A. J. Kazimi a déclaré une série d’achats sur le marché libre effectués automatiquement dans le cadre d’un plan de trading Rule 10b5-1 adopté le 14 novembre 2024. Entre le 2 juin 2025 et le 30 juin 2025, il a acheté environ 160 actions ordinaires en 20 petites transactions quotidiennes (principalement 8 actions, la dernière transaction 16 actions). Les prix d’achat variaient de 6,00 $ au début de la période à 2,60 $ en fin de mois, impliquant un coût moyen proche de 5,0 $ par action (≈ 800 $ au total).

La propriété directe de Kazimi est passée de 5 699 268 à 5 699 428 actions. Aucun instrument dérivé n’a été impliqué. Étant donné que les transactions représentent moins de 0,003% de sa participation existante et ont été planifiées à l’avance, le dépôt est principalement administratif, bien que l’achat régulier par un initié — malgré la baisse du cours de l’action — puisse être perçu comme un léger signe de confiance.

Cumberland Pharmaceuticals Inc. (CPIX) – Form 4 Einreichung, 11. Juli 2025

Der Vorsitzende, CEO und 10%-Eigentümer A. J. Kazimi meldete eine Reihe von automatischen Käufen am offenen Markt im Rahmen eines Rule 10b5-1 Handelsplans, der am 14. November 2024 eingeführt wurde. Zwischen dem 2. Juni 2025 und dem 30. Juni 2025 kaufte er etwa 160 Stammaktien in 20 kleinen täglichen Tranchen (meist 8 Aktien, die letzte Tranche 16 Aktien). Die Kaufpreise lagen zwischen 6,00 $ zu Beginn und 2,60 $ zum Monatsende, was auf durchschnittliche Kosten von etwa 5,0 $ pro Aktie (ca. 800 $ insgesamt) hindeutet.

Kazimis direkte Beteiligung stieg von 5.699.268 auf 5.699.428 Aktien. Es waren keine Derivate beteiligt. Da die Transaktionen weniger als 0,003% seines bestehenden Anteils ausmachen und vorab geplant waren, ist die Meldung überwiegend administrativer Natur, obwohl der kontinuierliche Insiderkauf – trotz fallender Aktienkurse – als kleines Vertrauenssignal gewertet werden kann.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KAZIMI A J

(Last) (First) (Middle)
1600 WEST END AVE.
SUITE 1300

(Street)
NASHVILLE TN 37203

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chairman and CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/02/2025 P V 8(1) A $5.2 5,699,268 D
Common Stock 06/03/2025 P V 8(1) A $5.61 5,699,276 D
Common Stock 06/04/2025 P V 8(1) A $5.75 5,699,284 D
Common Stock 06/05/2025 P V 8(1) A $5.46 5,699,292 D
Common Stock 06/06/2025 P V 8(1) A $5.57 5,699,300 D
Common Stock 06/09/2025 P V 8(1) A $5.94 5,699,308 D
Common Stock 06/10/2025 P V 8(1) A $6 5,699,316 D
Common Stock 06/11/2025 P V 8(1) A $5.57 5,699,324 D
Common Stock 06/12/2025 P V 8(1) A $5.67 5,699,332 D
Common Stock 06/13/2025 P V 8(1) A $5.81 5,699,340 D
Common Stock 06/16/2025 P V 8(1) A $5.32 5,699,348 D
Common Stock 06/17/2025 P V 8(1) A $5.61 5,699,356 D
Common Stock 06/18/2025 P V 8(1) A $5.52 5,699,364 D
Common Stock 06/20/2025 P V 8(1) A $5.29 5,699,372 D
Common Stock 06/23/2025 P V 8(1) A $4.61 5,699,380 D
Common Stock 06/24/2025 P V 8(1) A $3.91 5,699,388 D
Common Stock 06/25/2025 P V 8(1) A $3.27 5,699,396 D
Common Stock 06/26/2025 P V 8(1) A $2.71 5,699,404 D
Common Stock 06/27/2025 P V 8(1) A $2.6 5,699,412 D
Common Stock 06/30/2025 P V 16(1) A $2.74 5,699,428 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reported purchase occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024.
Remarks:
A.J. Kazimi by /s/ John Hamm as attorney-in-fact 07/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CPIX shares did CEO A. J. Kazimi buy according to the July 2025 Form 4?

He purchased about 160 common shares in June 2025.

What price range did the CPIX insider pay for the shares?

Prices ranged from $6.00 on 10 June to $2.60 on 27 June 2025.

Does Kazimi now own more than 5.7 million CPIX shares?

Yes. His direct beneficial ownership increased to 5,699,428 shares.

Were the transactions executed under a Rule 10b5-1 trading plan?

Yes. The filing states the purchases were automatic under a 10b5-1 plan adopted on 14 Nov 2024.

Is this insider activity considered material to CPIX investors?

Given the very small share count and pre-scheduled nature, the impact is generally viewed as neutral.
Cumberland Pharmaceuticals Inc

NASDAQ:CPIX

CPIX Rankings

CPIX Latest News

CPIX Latest SEC Filings

CPIX Stock Data

45.48M
8.74M
44.47%
22.13%
2.25%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE,